15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          G-protein α s (GNAS) mediates receptor-stimulated cAMP signaling, which integrates diverse environmental cues with intracellular responses. GNAS is mutationally activated in multiple tumor types, although its oncogenic mechanisms remain elusive. We explored this question in pancreatic tumorigenesis where concurrent GNAS and KRAS mutations characterize pancreatic ductal adenocarcinomas (PDAs) arising from Intraductal Papillary Mucinous Neoplasms (IPMNs). By developing genetically engineered mouse models, we show that GNAS R201C cooperates with KRAS G12D to promote initiation of IPMN, which progress to invasive PDA following Tp53 loss. Mutant-GNAS remains critical for tumor maintenance in vivo. This is driven by protein kinase A-mediated suppression of salt-inducible kinases (SIK1-3), associated with induction lipid remodeling and fatty acid oxidation. Comparison of KRAS-mutant pancreatic cancer cells with and without GNAS mutations reveals striking differences in the functions of this network. Thus, we uncover GNAS-driven oncogenic mechanisms, identify SIKs as potent tumor suppressors, and demonstrate unanticipated metabolic heterogeneity among KRAS-mutant pancreatic neoplasms.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: found

          Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

          Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting role is highly context dependent. Oncogenic Kras mutation is the signature event in pancreatic ductal adenocarcinoma (PDAC), serving a critical role in tumor initiation. Here, an inducible Kras(G12D)-driven PDAC mouse model establishes that advanced PDAC remains strictly dependent on Kras(G12D) expression. Transcriptome and metabolomic analyses indicate that Kras(G12D) serves a vital role in controlling tumor metabolism through stimulation of glucose uptake and channeling of glucose intermediates into the hexosamine biosynthesis and pentose phosphate pathways (PPP). These studies also reveal that oncogenic Kras promotes ribose biogenesis. Unlike canonical models, we demonstrate that Kras(G12D) drives glycolysis intermediates into the nonoxidative PPP, thereby decoupling ribose biogenesis from NADP/NADPH-mediated redox control. Together, this work provides in vivo mechanistic insights into how oncogenic Kras promotes metabolic reprogramming in native tumors and illuminates potential metabolic targets that can be exploited for therapeutic benefit in PDAC. Copyright © 2012 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

            (2017)
            We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.

              The Hippo pathway is crucial in organ size control, and its dysregulation contributes to tumorigenesis. However, upstream signals that regulate the mammalian Hippo pathway have remained elusive. Here, we report that the Hippo pathway is regulated by G-protein-coupled receptor (GPCR) signaling. Serum-borne lysophosphatidic acid (LPA) and sphingosine 1-phosphophate (S1P) act through G12/13-coupled receptors to inhibit the Hippo pathway kinases Lats1/2, thereby activating YAP and TAZ transcription coactivators, which are oncoproteins repressed by Lats1/2. YAP and TAZ are involved in LPA-induced gene expression, cell migration, and proliferation. In contrast, stimulation of Gs-coupled receptors by glucagon or epinephrine activates Lats1/2 kinase activity, thereby inhibiting YAP function. Thus, GPCR signaling can either activate or inhibit the Hippo-YAP pathway depending on the coupled G protein. Our study identifies extracellular diffusible signals that modulate the Hippo pathway and also establishes the Hippo-YAP pathway as a critical signaling branch downstream of GPCR. Copyright © 2012 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                100890575
                21417
                Nat Cell Biol
                Nat. Cell Biol.
                Nature cell biology
                1465-7392
                1476-4679
                16 May 2018
                25 June 2018
                July 2018
                25 December 2018
                : 20
                : 7
                : 811-822
                Affiliations
                [1 ]Center for Cancer Research
                [2 ]Department of Pathology
                [3 ]Department of Surgery
                [4 ]Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA
                [5 ]Departments of Medicine
                [6 ]Department of Pathology
                [7 ]Department of Surgery
                [8 ]Department of Genetics, Harvard Medical School, Boston, MA 02115 USA
                [9 ]Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido 065-0033, JAPAN
                [10 ]Departments of Nutritional Sciences and Toxicology, Chemistry, and Molecular and Cell Biology, University of California, Berkeley, CA 94720 USA
                [11 ]Sunnybrook Research Institute, Toronto, Canada, M4N 3M5, Dept. of Biochemistry, University of Toronto, Toronto, Canada, M5S 1A8
                [12 ]MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Scotland, UK
                Author notes
                Bardeesy.Nabeel@ 123456mgh.harvard.edu ; Phone: 617-643-2579; Fax: 617-643-3170
                [*]

                Present Address: Asahikawa Medical University, Hokkaido, Japan

                [^]

                Present Address: Nestlé Institute of Health Sciences SA, Lausanne, Switzerland

                Article
                NIHMS968400
                10.1038/s41556-018-0122-3
                6044476
                29941929
                9db4be10-23ae-4cf9-97d1-a83d8afd50be

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Cell biology
                pancreatic cancer,ipmn,cancer metabolism,gnas,pka,kras
                Cell biology
                pancreatic cancer, ipmn, cancer metabolism, gnas, pka, kras

                Comments

                Comment on this article